Whan In PharmLtd Full Year 2024 Earnings: EPS Beats Expectations

Whan In PharmLtd (KRX:016580) Full Year 2024 Results

Key Financial Results

• Revenue: ₩259.6b (up 13% from FY 2023).
• Net income: ₩23.4b (down 22% from FY 2023).
• Profit margin: 9.0% (down from 13% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: ₩1,531 (down from ₩1,950 in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Whan In PharmLtd EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 17%.

Looking ahead, revenue is forecast to grow 6.7% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea.

Performance of the South Korean Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Whan In PharmLtd you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.